Targeting leukemia initiating cells is considered to be an effective way to cure leukemia， for which it is critical to identify novel therapeutic targets. Herein， we demonstrate that CD244， which was initially reported as a key regulator for natural killer cells， is highly expressed on both mouse and human leukemia initiating cells. Upon CD244 knockdown， human leukemia cell lines and primary leukemia cells have markedly impaired proliferation abilities both and Interestingly， the repopulation ability of both mouse and human hematopoietic stem cells is not impaired upon CD244 knockdown. Using an MLL-AF9-induced murine acute myeloid leukemia model， we show that leukemogenesis is dramatically delay... More
Targeting leukemia initiating cells is considered to be an effective way to cure leukemia， for which it is critical to identify novel therapeutic targets. Herein， we demonstrate that CD244， which was initially reported as a key regulator for natural killer cells， is highly expressed on both mouse and human leukemia initiating cells. Upon CD244 knockdown， human leukemia cell lines and primary leukemia cells have markedly impaired proliferation abilities both and Interestingly， the repopulation ability of both mouse and human hematopoietic stem cells is not impaired upon CD244 knockdown. Using an MLL-AF9-induced murine acute myeloid leukemia model， we show that leukemogenesis is dramatically delayed upon CD244 deletion， together with remarkably reduced Mac1/c-Kit leukemia cells (enriched for leukemia initiating cells). Mechanistically， we reveal that CD244 is associated with c-Kit and p27 except for SHP-2 as previously reported. CD244 co-operates with c-Kit to activate SHP-2 signaling to dephosphorylate p27 and maintain its stability to promote leukemia development. Collectively， we provide intriguing evidence that the surface immune molecule CD244 plays an important role in the maintenance of stemness of leukemia initiating cells， but not in hematopoietic stem cells. CD244 may represent a novel therapeutic target for the treatment of acute myeloid leukemia.
